Company: NIVFW
Filing Date: 2025-05-20
Form Type: F-1/A
Source: 0001213900-25-045737
Chunk: 1

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-20
Form: F-1/A
Chunk 1
---
 check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

22,027,500 Class A Ordinary Shares NewGenIvf Group Limited This prospectus relates to the resale by the selling securityholders identified in this prospectus (“Selling Securityholders”) of up to 22,027,500 Class A Ordinary Shares, no par value per share (“Class A Ordinary Shares”), consisting of (i) 12,500 Class A Ordinary Shares issued to Genetics & IVF Institute, Inc. (“GIVF”) in connection with the Purchase Agreement dated as of January 21, 2025, by and between the Company and GIVF (“MicroSort Purchase Agreement”); and (ii) 15,000 Class A Ordinary Shares issued to A SPAC Holdings Group Corp. (“ASPAC”) in connection with a consulting services agreement dated as of February 24, 2025, by and between the Company and ASPAC (“ASPAC Agreement”); (iii) an additional 12,000,000 Class A Ordinary Shares issuable to JAK Opportunities VI LLC upon the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (“Exchange